Pharmaceutical A | Â | Pharmaceutical B |
---|---|---|
Average (5Â years) | Survival | Low (1Â year) |
High improvement in QoL (50%) | Quality of life | Low improvement QoL (15%) |
No | Alternative treatment | Yes |
5Â years | Age group | 18 to 60Â years |
High: 500 million IRR (11,900 US dollar) | Cost to government | High: 500 million IRR (11,900 US dollar) |
Severe: low longevity (up to 3Â month); low QoL (30%) | Disease severity | Mild: high longevity (15Â years), moderate QoL (60%) |
Domestic production | Drug manufacturer country | Imported |
Which pharmaceutical do you prefer to be subsidized? Pharmaceutical A Pharmaceutical B |